Form 4: Director Roger Jeffs Sells Axsome Shares for Tax Coverage

Director Roger Jeffs sold a total of 572 shares of Axsome Therapeutics common stock to cover tax obligations related to RSU settlements.

Summary

• Director Roger Jeffs executed the sale of 572 shares of Axsome Therapeutics (AXSM) common stock.
• The sales occurred on June 10, 2026 (286 shares at $246.18) and June 11, 2026 (286 shares at $249.12).
• The transactions were conducted under a pre-approved Rule 10b5-1 trading plan.
• The purpose of the sale was specifically to cover tax withholding obligations resulting from the settlement of Restricted Stock Units (RSUs) granted in 2025.
• Following these transactions, the reporting person retains beneficial ownership of 58,367 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a strategic shift or market signal.

Positives

• The sale was executed under a pre-approved 10b5-1 plan, indicating the transaction was scheduled in advance and not based on non-public information.
• The transaction was routine, specifically intended to satisfy tax obligations rather than a discretionary divestment of equity.

Negatives

• The sale represents a reduction in the director's direct equity stake in the company.

Risks

• None identified; this is a standard administrative transaction for tax compliance.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling to cover tax obligations upon the vesting of equity awards is a standard corporate governance practice and typically does not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for directors and executives to manage equity holdings while avoiding potential insider trading concerns.
• The sale of shares to cover tax withholding is a common practice among biotechnology executives following the vesting of RSU grants.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and limited in volume.

Next Steps

• Completion of the 10b5-1 plan as noted in the filing.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Director Sale, 10b5-1